These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. One-year clinical results of the NANO registry: A multicenter, prospective all-comers registry study in patients receiving implantation of a polymer-free sirolimus-eluting stent. Liu Y; Zhang Y; Li Y; Qi T; Pan D; Wang H; Liu C; Ma D; Fang Z; Zhang R; Mou F; Tao L; Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():658-664. PubMed ID: 31961057 [TBL] [Abstract][Full Text] [Related]
13. Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial. Ellert J; Christiansen EH; Maeng M; Raungaard B; Jensen SE; Kristensen SD; Veien KT; Junker AB; Jakobsen L; Aarøe J; Terkelsen CJ; Kahlert J; Villadsen AB; Bøtker HE; Jensen LO Catheter Cardiovasc Interv; 2019 Mar; 93(4):567-573. PubMed ID: 30244533 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. Iglesias JF; Heg D; Roffi M; Tüller D; Noble S; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Häner J; Jüni P; Windecker S; Pilgrim T Circ Cardiovasc Interv; 2019 Aug; 12(8):e008024. PubMed ID: 31525083 [TBL] [Abstract][Full Text] [Related]
16. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry. Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K; JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178 [TBL] [Abstract][Full Text] [Related]
17. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698 [TBL] [Abstract][Full Text] [Related]
18. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent). Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes. Kakizaki R; Minami Y; Katamine M; Katsura A; Muramatsu Y; Hashimoto T; Meguro K; Shimohama T; Ako J Cardiovasc Diabetol; 2020 Oct; 19(1):162. PubMed ID: 33004019 [TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy. Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]